関節リウマチにおける抗リウマチ薬後のトファシチニブ: NICE Single Technology Appraisal における Evidence Review Groupの展望
Pharmacoeconomics 2018 Sep; 36(9): 1063–72
In this National Institute for Health and Care (NICE) single technology appraisal of tofacitinib (TOF) plus methotrexate (MTX), TOF had similar efficacy and comparable costs to recommended bDMARDs plus MTX in patients with RA. NICE is an independent organisation responsible for providing national guidance on health technologies in England. To be recommended by NICE, the company must provide evidence to prove TOF’s effectiveness, both clinically and costly. This evidence based review, reports the...